September 16, 2016

NRG-GY008: "A Phase II Evaluation of Copanlisib (BAY 80-6946) (Ind #130822), A Selective Inhibitor of PI3KCA, in Patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations” is active.
NCI Version Date: 08/18/2016

Please see the NRG Oncology website for details.

Twitter
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address